PRESS RELEASES

Date	Title
Apr 12, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
Apr 11, 2022	Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
Apr 7, 2022	Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings
Apr 4, 2022	Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
Mar 9, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
Mar 2, 2022	Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference
Feb 28, 2022	Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Feb 24, 2022	Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners
Feb 22, 2022	Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
Feb 4, 2022	Ardelyx, Inc. Reports Employment Inducement Grants

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com